论文部分内容阅读
此文的目的是为了评价一种Ⅲ型抗心律失常药物:胺碘酮(Amioderone)单用或合用心得安治疗儿童致命性或抗药性的快速型心律失常的效果.研究对象为患有致命性或抗药性的室上性或室性快速型心律失常的27例患儿(平均年龄3个月);胺碘酮的负荷量是10-12mg/(kg·次),维持剂量3~20mg/(kg·d)当单用胺碘酮无效时,加用心得安,剂量为2-4mg/(kg·d).27名患儿分为两组:＜1岁为A组:＞1岁为B组.治疗效果的评估通过临床评价,24小时动态心电图监测,运动试验,心律失常的复发及电生理试验.结果显示:胺碘酮单用有效率A组为
The purpose of this article is to evaluate the efficacy of Amioderone alone or in combination with propranolol in the management of lethal or drug resistant tachyarrhythmia in children who are either fatal 27 patients (average age, 3 months) with drug-resistant supraventricular or ventricular tachyarrhythmia; amiodarone loading was 10-12 mg / (kg • time), maintenance dose 3 to 20 mg / ( kg · d) When using amiodarone alone, add propranolol in a dose of 2-4mg / (kg · d) .27 children were divided into two groups: <1 year old group A:> 1 year old Group B. The evaluation of the therapeutic effect through clinical evaluation, 24-hour Holter monitoring, exercise test, arrhythmia recurrence and electrophysiological test results showed that: Amiodarone group A